GYRE
Gyre Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.79 / 10
Netural
Capital flow assessment yields 7.59/10, denoting robust fund flow characteristics. Strengths in block, Small, and Extra-large trends confront pressures from overall, Medium, and Large patterns, resulting in positive liquidity outlook. Analyst coverage indicates overwhelmingly bullish analyst consensus with strong conviction. Rating distribution: Strong Buy(100.0%) among 1 analysts, supported by 0.00 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-10
InstitutionJefferies
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for GYRE?
- GYRE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.79/10 (Netural).
